Qingdao Baheal Medical Inc
SZSE:301015
Intrinsic Value
Qingdao Baheal Medical, Inc. engages in the provision of marketing services for pharmaceutical product manufacturers. [ Read More ]
The intrinsic value of one Qingdao Baheal Medical Inc stock under the Base Case scenario is 38.83 CNY. Compared to the current market price of 32.35 CNY, Qingdao Baheal Medical Inc is Undervalued by 17%.
Valuation Backtest
Qingdao Baheal Medical Inc
Run backtest to discover the historical profit from buying and selling Qingdao Baheal Medical Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Qingdao Baheal Medical Inc
| Current Assets | 4.6B |
| Cash & Short-Term Investments | 1.2B |
| Receivables | 2.3B |
| Other Current Assets | 1.1B |
| Non-Current Assets | 853m |
| Long-Term Investments | 300.3m |
| PP&E | 434.4m |
| Intangibles | 59.5m |
| Other Non-Current Assets | 58.8m |
| Current Liabilities | 2.2B |
| Accounts Payable | 615.9m |
| Accrued Liabilities | 103.9m |
| Short-Term Debt | 1.2B |
| Other Current Liabilities | 293.9m |
| Non-Current Liabilities | 837.4m |
| Long-Term Debt | 866.8m |
| Other Non-Current Liabilities | -29.5m |
Earnings Waterfall
Qingdao Baheal Medical Inc
|
Revenue
|
7.5B
CNY
|
|
Cost of Revenue
|
-5.3B
CNY
|
|
Gross Profit
|
2.2B
CNY
|
|
Operating Expenses
|
-1.3B
CNY
|
|
Operating Income
|
883.7m
CNY
|
|
Other Expenses
|
-231.2m
CNY
|
|
Net Income
|
652.5m
CNY
|
Free Cash Flow Analysis
Qingdao Baheal Medical Inc
Profitability Score
Profitability Due Diligence
Qingdao Baheal Medical Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Qingdao Baheal Medical Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Qingdao Baheal Medical Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Qingdao Baheal Medical Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Qingdao Baheal Medical Inc
According to Wall Street analysts, the average 1-year price target for Qingdao Baheal Medical Inc is 52.02 CNY with a low forecast of 51.51 CNY and a high forecast of 53.55 CNY.
Shareholder Return
Price
Qingdao Baheal Medical Inc
| Average Annual Return | -31.62% |
| Standard Deviation of Annual Returns | 21.45% |
| Max Drawdown | -67% |
| Market Capitalization | 17B CNY |
| Shares Outstanding | 525 613 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Qingdao Baheal Medical, Inc. engages in the provision of marketing services for pharmaceutical product manufacturers. The company is headquartered in Qingdao, Shandong and currently employs 2,396 full-time employees. The company went IPO on 2021-06-30. The firm provides brand operation, wholesale distribution and retail services for pharmaceutical products. Its brand operation services include consumer education, product academic promotion, marketing planning, business contacts, product distribution, flow tracking and supply chain management services. The firm's wholesale distribution business mainly centers on Qingdao and Beijing, and radiates second-level and above hospitals, community clinics and pharmacies in surrounding cities. Its wholesale distribution products include medicines, Chinese herbal medicine pieces, medical equipment, diagnostic reagents, medical consumables, among others. The firm mainly conducts its business within domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one Qingdao Baheal Medical Inc stock under the Base Case scenario is 38.83 CNY.
Compared to the current market price of 32.35 CNY, Qingdao Baheal Medical Inc is Undervalued by 17%.
You don't have any saved screeners yet
